Background The aim of the present meta-analysis was to evaluate the effectiveness and
safety of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …

Background Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …

Aims Polypharmacy is prevalent among non-valvular atrial fibrillation (NVAF) patients and
presents a potential issue for the effective management of NVAF. This study compared the …

Background: Current guidelines recommend non–vitamin K antagonist oral anticoagulants
(NOACs) as the first-choice therapy in patients with nonvalvular atrial fibrillation because …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) are effective and safe
alternatives compared with vitamin K antagonists (VKAs) for thromboembolic prevention in …

Background Off-label dosing non–vitamin K antagonist oral anticoagulants (NOACs) are
commonly prescribed for Asian patients with atrial fibrillation (AF). Objective The purpose of …

Aim Non‐vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …

Background Atrial fibrillation (AF) is the most common cardiac arrhythmia associated with an
increased risk of stroke and thromboembolism. Anticoagulation with Vitamin K antagonists …

Background Warfarin, despite its known limitations, is the reference standard treatment for
patients with AF and risk factors for stroke. We performed a meta-analysis of phase III trials …